NASDAQ:ORGS - Orgenesis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.27
▲ +0.37 (7.55%)

This chart shows the closing price for ORGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orgenesis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORGS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Orgenesis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.27.

This chart shows the closing price for ORGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Orgenesis. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2019BenchmarkInitiated CoverageBuy$9.00 ➝ $9.00Low
12/20/2018Dawson JamesReiterated RatingBuyHigh
12/20/2018Dawson JamesInitiated CoverageBuy ➝ BuyMedium
(Data available from 6/24/2016 forward)
Orgenesis logo
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was incorporated in 2008 and is based in Germantown, Maryland.
Read More

Today's Range

Now: $5.27
Low: $4.81
High: $5.30

50 Day Range

MA: $4.93
Low: $4.19
High: $5.66

52 Week Range

Now: $5.27
Low: $4.14
High: $8.30

Volume

230,772 shs

Average Volume

328,060 shs

Market Capitalization

$129.01 million

P/E Ratio

273.50

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Orgenesis?

The following Wall Street analysts have issued stock ratings on Orgenesis in the last year:
View the latest analyst ratings for ORGS.

What is the current price target for Orgenesis?

0 Wall Street analysts have set twelve-month price targets for Orgenesis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Orgenesis in the next year.
View the latest price targets for ORGS.

What is the current consensus analyst rating for Orgenesis?

Orgenesis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ORGS.

What other companies compete with Orgenesis?

How do I contact Orgenesis' investor relations team?

Orgenesis' physical mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company's listed phone number is 480 659 6404 and its investor relations email address is [email protected] The official website for Orgenesis is www.orgenesis.com.